Lercanidipino Normon (Lercanidipine Hydrochloride)

Lercanidipino Normon is a calcium channel blocker indicated for the management of hypertension and related cardiovascular conditions.

• Essential hypertension: lowers systolic and diastolic blood pressure to achieve target levels.
• Isolated systolic hypertension: helps control elevated systolic pressure, especially in older adults.
• Hypertension with coronary artery disease: reduces cardiac workload while maintaining coronary perfusion.

• Lercanidipine Hydrochloride selectively inhibits L-type calcium channels in vascular smooth muscle cells, preventing calcium influx that is required for contraction. This vasodilatory effect reduces peripheral vascular resistance, leading to a decrease in arterial blood pressure without significant negative inotropic effects on the heart.

Lercanidipino Normon may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Headache: mild to moderate intensity.
• Flushing: warm sensation, usually on the face or neck.
• Peripheral edema: swelling of ankles or feet.
• Dizziness or light‑headedness.
• Tachycardia: increased heart rate.
• Fatigue or general weakness.

Serious or Rare Side Effects

• Angioedema: swelling of lips, tongue, or throat requiring emergency care.
• Severe hypotension: marked drop in blood pressure causing fainting.
• Myocardial infarction: rare occurrence of heart attack.
• Hepatic dysfunction: elevated liver enzymes.
• Allergic reactions: rash, pruritus, or anaphylaxis.
• Cardiac arrhythmias: irregular heart rhythms.

When prescribing Lercanidipino Normon, clinicians should consider several safety measures.

• Blood pressure monitoring: ensure adequate control and avoid excessive hypotension.
• Hepatic impairment: use with caution; dose adjustment may be required.
• Concomitant antihypertensives: assess risk of additive blood‑pressure lowering effects.
• Sudden discontinuation: taper gradually to prevent rebound hypertension.
• Pregnancy and lactation: evaluate risk‑benefit; limited data available.
• Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Lercanidipino Normon can interact with several drug classes, influencing its efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma levels and risk of toxicity.
• Grapefruit juice: can markedly raise drug concentration.
• Concurrent use with other potent antihypertensives: may cause severe hypotension.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect.

• Non‑dihydropyridine calcium channel blockers: additive cardiovascular effects.
• Diuretics: monitor electrolytes and renal function.
• Beta‑blockers: watch for bradycardia or excessive blood‑pressure reduction.